Rapid Immunodiagnosis of Drug-Resistant Bacterial Pathogens

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41AI108029-01A1
Agency Tracking Number: R41AI108029
Amount: $600,000.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NIAID
Solicitation Number: PA10-124
Timeline
Solicitation Year: 2015
Award Year: 2014
Award Start Date (Proposal Award Date): 2014-04-10
Award End Date (Contract End Date): 2016-09-30
Small Business Information
1300 West Optical Dr., Suite 300, Azusa, CA, 91702-3284
DUNS: 874892821
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 MARK GEISBERG
 (626) 359-8441
 mgeisberg@silverlakeresearch.com
Business Contact
 MARK GEISBERG
Phone: (626) 359-8441
Email: mgeisberg@silverlakeresearch.com
Research Institution
 UNIVERSITY OF CALIFORNIA BERKELEY
 2150 SHATTUCK AVENUE, RM 313
BERKELEY, CA, 94704-5940
 Nonprofit college or university
Abstract
DESCRIPTION provided by applicant Bacterial resistance to lactam antibiotics is threatening to limit the effectiveness of this most used class of antibiotics A major contributin factor to this problem is the lack of rapid testing methods for medical practitioners to identify lactam resistant pathogens before prescribing specific antibiotics For urinary tract infections UTIs the most common bacterial infections in the world older lactam antibiotics are not used despite the fact that andgt of uropathogens are sensitive to these drugs Resistance to lactam antibiotics is conferred by the expression of lactamases enzymes that deactivate the antibiotics We propose the development of a rapid immunoassay test kit for detection of any of a wide range of lactamases In Phase I of this project we aim to develop cross reactive monoclonal antibodies MAbs targeting the homologous regions of the most clinically problematic classes of lactamases extended spectrum lactamases ESBLs and carbapenemases and then to develop a sandwich ELISA capable of distinguishing lactam resistant clinical bacterial isolates from lactam sensitive isolates In Phase II we will aim to convert this laboratory ELISA into a robust minute lateral flow immunoassay test kit similar to the home pregnancy test capable of detecting lactamases and therefore lactam resistance directly in patient samples This capability promises to revolutionize current clinical practice for treatment of UTIs allowing the effective use of even the earliest lactams and preventing the selection of resistance to current first line treatments PUBLIC HEALTH RELEVANCE A major contributing factor to the problem of bacterial resistance to antibiotics is the lack of rapid testing methods for medical practitioners to identif lactam resistant pathogens before prescribing specific antibiotics We propose the development of a rapid test kit to detect resistance to lactam antibiotics directly in urine samples of patients with urinary tract infections This capability promises to allow the targeted use of antibiotics on sensitive pathogens resurrecting the effectiveness of older drugs and preventing the selection of resistance to current first line treatments

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government